Quick Answer
HALOZYME THERAPEUTICS, INC. reported Net Income Loss of $316.89 million for the year ending 2025.
- HALOZYME THERAPEUTICS, INC. showed a decrease of -28.6% in Net Income Loss from 2024 to 2025.
- This data is from HALOZYME THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), HALOZYME THERAPEUTICS, INC.'s Net Income Loss has grown by 643.0%.
- Historical annual values: Fiscal year 2025: $316.89 million | Fiscal year 2024: $444.09 million | Fiscal year 2023: $281.59 million | Fiscal year 2022: $202.13 million | Fiscal year 2021: $402.71 million | Fiscal year 2020: $129.09 million | Fiscal year 2019: -$72.24 million | Fiscal year 2018: -$80.33 million | Fiscal year 2017: $62.97 million | Fiscal year 2016: -$103.02 million | Fiscal year 2015: -$32.23 million | Fiscal year 2014: -$68.38 million | Fiscal year 2013: -$83.48 million | Fiscal year 2012: -$53.55 million | Fiscal year 2011: -$19.77 million | Fiscal year 2010: -$53.24 million | Fiscal year 2009: -$58.36 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: